Status:
RECRUITING
The Incidence of Hyperfibrinolysis During Vaginal Delivery and Cesarean Section
Lead Sponsor:
Medical University of Graz
Conditions:
Hyperfibrinolysis
Cesarean Section Complications
Eligibility:
FEMALE
18+ years
Brief Summary
This study aims to find out if there are common major changes in coagulation immediately after delivery of the newborn during Cesarean (C) -section and vaginal birth.
Detailed Description
Postpartum Hemorrhage (PPH) is a potentially life-threatening complication of labour and a leading cause of maternal mortality and morbidity. It is defined as a blood loss of 500ml or more in the firs...
Eligibility Criteria
Inclusion
- Women aged 18 years and older with a singleton or multiple pregnancy who volunteer for the present study and give one blood sample of 6ml
Exclusion
- Age \< 18 years
- Emergency cesarean section
- History of thrombocytopathy or coagulation disorders
- Therapy with drugs that influence thrombocyte function and coagulation (ASS less than 5 days ago, clopidogrel, prasugrel, ticagrelor or similar)
- Lack of consent
Key Trial Info
Start Date :
June 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 17 2025
Estimated Enrollment :
780 Patients enrolled
Trial Details
Trial ID
NCT05975112
Start Date
June 1 2023
End Date
April 17 2025
Last Update
March 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz
Graz, Styria, Austria, 8010